These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 5645223)

  • 1. Sequence of events in mice early in immunologic paralysis by pneumococcal polysaccharide.
    Matangkasombut P; Seastone CV
    J Immunol; 1968 Apr; 100(4):845-50. PubMed ID: 5645223
    [No Abstract]   [Full Text] [Related]  

  • 2. Direct evidence for the involvement of T suppressor cells in the expression of low-dose paralysis to type III pneumococcal polysaccharide.
    Baker PJ; Amsbaugh DF; Stashak PW; Caldes G; Prescott B
    J Immunol; 1982 Mar; 128(3):1059-62. PubMed ID: 6173416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MECHANISMS OF IMMUNOLOGIC PARALYSIS BY PNEUMOCOCCAL POLYSACCHARIDE. I. STUDIES OF ADOPTIVELY ACQUIRED IMMUNITY TO PNEUMOCOCCAL INFECTION IN IMMUNOLOGICALLY PARALYZED AND NORMAL MICE.
    NEEPER CA; SEASTONE CV
    J Immunol; 1963 Sep; 91():374-7. PubMed ID: 14071028
    [No Abstract]   [Full Text] [Related]  

  • 4. MECHANISMS OF IMMUNOLOGIC PARALYSIS BY PNEUMOCOCCAL POLYSACCHARIDE. II. THE INFLUENCE OF NONSPECIFIC FACTORS ON THE IMMUNITY OF PARALYZED MICE TO PNEUMOCOCCAL INFECTION.
    NEEPER CA; SEASTONE CV
    J Immunol; 1963 Sep; 91():378-83. PubMed ID: 14071029
    [No Abstract]   [Full Text] [Related]  

  • 5. Studies on immunological paralysis. IV. The relative contributions of continuous antibody neutralization and central inhibition to paralysis with type 3 pneumococcal polysaccharide.
    Howard JG; Christie GH; Courtenay BM
    Proc R Soc Lond B Biol Sci; 1971 Sep; 178(1053):417-38. PubMed ID: 4398678
    [No Abstract]   [Full Text] [Related]  

  • 6. Impaired anti-pneumococcal polysaccharide antibody production and invasive pneumococcal infection following heart transplantation.
    Sarmiento E; Rodríguez-Hernández C; Rodríguez-Molina J; Fernández-Yánez J; Palomo J; Anguita J; Pérez JL; Lanio N; Fernández-Cruz E; Carbone J
    Int Immunopharmacol; 2006 Dec; 6(13-14):2027-30. PubMed ID: 17161358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide mimics of two pneumococcal capsular polysaccharide serotypes (6B and 9V) protect mice from a lethal challenge with Streptococcus pneumoniae.
    Smith CM; Lo Passo C; Scuderi A; Kolberg J; Baxendale H; Goldblatt D; Oggioni MR; Felici F; Andrew PW
    Eur J Immunol; 2009 Jun; 39(6):1527-35. PubMed ID: 19499518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement dependency of splenic localization of pneumococcal polysaccharide and conjugate vaccines.
    Breukels MA; Zandvoort A; Rijkers GT; Lodewijk ME; Klok PA; Harms G; Timens W
    Scand J Immunol; 2005 Apr; 61(4):322-8. PubMed ID: 15853914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies against pneumococcal C-polysaccharide are not protective.
    Nielsen SV; Sørensen UB; Henrichsen J
    Microb Pathog; 1993 Apr; 14(4):299-305. PubMed ID: 8326853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Invasive pneumococcal infections in patients with primary immunodeficiency disorders].
    Erdos M; Maródi L
    Orv Hetil; 2006 Apr; 147(17):799-804. PubMed ID: 16780188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody to capsular polysaccharide of Streptococcus pneumoniae at the time of hospital admission for Pneumococcal pneumonia.
    Musher DM; Phan HM; Watson DA; Baughn RE
    J Infect Dis; 2000 Jul; 182(1):158-67. PubMed ID: 10882593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pneumococcal conjugate vaccine primes for polysaccharide-inducible IgG2 antibody response in children with recurrent otitis media acuta.
    Breukels MA; Rijkers GT; Voorhorst-Ogink MM; Zegers BJ; Sanders LA
    J Infect Dis; 1999 May; 179(5):1152-6. PubMed ID: 10191217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyvalent 23 epitope polysaccharide pneumonia vaccine induced effective protection through strain-adapted effector mechanisms as demonstrated by the different cytokine responses in mice challenged with two different strains of Streptococcus pneumoniae.
    Mohler J; Moine P; Azoulay-Dupuis E; Henin D; Fantin B
    Eur Cytokine Netw; 2007 Mar; 18(1):23-30. PubMed ID: 17400535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
    Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y
    Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IC31, a two-component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice.
    Olafsdottir TA; Lingnau K; Nagy E; Jonsdottir I
    Scand J Immunol; 2009 Mar; 69(3):194-202. PubMed ID: 19281531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumococcal polysaccharide vaccines.
    Werre JM; de Haan LD
    Neth J Med; 2005 Apr; 63(4):152. PubMed ID: 15869046
    [No Abstract]   [Full Text] [Related]  

  • 17. The human polysaccharide- and protein-specific immune response to Streptococcus pneumoniae is dependent on CD4(+) T lymphocytes, CD14(+) monocytes, and the CD40-CD40 ligand interaction.
    Moens L; Wuyts G; Boon L; den Hartog MT; Ceuppens JL; Bossuyt X
    J Allergy Clin Immunol; 2008 Dec; 122(6):1231-3. PubMed ID: 18842293
    [No Abstract]   [Full Text] [Related]  

  • 18. A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin's lymphoma.
    Landgren O; Björkholm M; Konradsen HB; Söderqvist M; Nilsson B; Gustavsson A; Axdorph U; Kalin M; Grimfors G
    J Intern Med; 2004 Jun; 255(6):664-73. PubMed ID: 15147530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early life T cell responses to pneumococcal conjugates increase with age and determine the polysaccharide-specific antibody response and protective efficacy.
    Jakobsen H; Hannesdottir S; Bjarnarson SP; Schulz D; Trannoy E; Siegrist CA; Jonsdottir I
    Eur J Immunol; 2006 Feb; 36(2):287-95. PubMed ID: 16385627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Host reactions against bacteria. Application to pneumococcal infections].
    Mouton Y; Beaucaire G
    Bull Eur Physiopathol Respir; 1983; 19(2):191-4. PubMed ID: 6871496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.